Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Betting On Egalet Corp (EGLT)

Page 1 of 2

Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly interesting group of stocks that hedge funds like is the small-caps. The huge amount of capital does not allow hedge funds to invest a lot in small-caps, but our research showed that their most popular small-cap ideas are less efficiently priced and generate stronger returns than their large- and mega-cap picks and the broader market. That is why we follow the hedge fund activity in the small-cap space.

As many of its industry peers, shares of the biotech company Egalet Corp (NASDAQ:EGLT) have seen a 70% boost since the beginning of the year, which has, in turn, led to an increase in interest from smart money investors. In this way, EGLT was in 10 hedge funds’ portfolios at the end of the third quarter of 2015, versus 3 hedge funds in our database with EGLT holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Peapack-Gladstone Financial Corp (NASDAQ:PGC), Covenant Transportation Group, Inc. (NASDAQ:CVTI), and Petmed Express Inc (NASDAQ:PETS) to gather more data points.

Follow Egalet Corp (NASDAQ:EGLT)
Trade (NASDAQ:EGLT) Now!

At the moment there are a lot of tools shareholders can use to analyze their stock investments. A duo of the most under-the-radar tools are hedge fund and insider trading signals. Our experts have shown that, historically, those who follow the top picks of the best investment managers can outperform their index-focused peers by a healthy margin (see the details here).

Now, we’re going to go over the key action regarding Egalet Corp (NASDAQ:EGLT).

Hedge fund activity in Egalet Corp (NASDAQ:EGLT)

At the end of the third quarter, a total of 10 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 233% from one quarter earlier. With hedgies’ positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers who were upping their holdings meaningfully (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Broadfin Capital, managed by Kevin Kotler, holds the most valuable position in Egalet Corp (NASDAQ:EGLT). Broadfin Capital has a $15 million position in the stock, comprising 0.8% of its 13F portfolio. Coming in second is Deerfield Management, managed by James E. Flynn, which holds a $6.3 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Remaining professional money managers that are bullish comprise Behzad Aghazadeh’s venBio Select Advisor, Kris Jenner, Gordon Bussard, Graham McPhail’s Rock Springs Capital Management, and D. E. Shaw’s D E Shaw.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!